Genentech, Inc.

Takeda Pharmaceutical Company Limited

Array Biopharma Inc.

Christopher Stephen Siedem

James F Blake

Eli M Wallace

Steven Armen Boyd

Huifen Chen

Mark Joseph Chicarelli

John Joseph Gaudino

Jacob Bradley Schwarz

Albert Charles Gyorkos

Peter J Mohr

Christopher Peter Corrette

Kazuyoshi Aso

Michiyo Mochizuki

Rustam Ferdinand Garrey

Suk Young Cho

Robert J Kaus

Jason Demeese

Gabrielle R Kolakowski

Kevin Ronald Condroski

Li Ren

David A Moreno

Lewis J Gazzard

Allison L Marlow

Masakuni Kori

Allen A Thomas

Samuel S Kintz

Steven Mark Wenglowsky

Scott Alan Pratt

Timothy Mark Turner

Compounds having the formula (I) wherein R, R, Rand Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Substituted quinazolines as serine/threonine kinase inhibitors

Compounds having the formula I wherein Z, ZZZ, R, Rand Rand as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Serine/threonine kinase inhibitors

There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or &#x2014;NR&#x2014; (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, &#x2014;CO&#x2014;, oxygen, sulfur, &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;NR&#x2014;, &#x2014;NR-alk-, &#x2014;CONR&#x2014; or &#x2014;NRCO&#x2014; (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.

Fused heterocyclic compounds

There is provided a CRF receptor antagonist comprising a compound of the formula (I):A-W&#x2014;Ar&#x2003;&#x2003;(I) 

Cyclic compounds

Growing community of inventors

Boulder, CO, United States of America

Christopher Stephen Siedem